The proliferation of health data in our ever more digitalised world of health care creates opportunities for better research around – and delivery of – pharmaceutical innovation. However, these opportunities may be constrained around the legal barriers to the use of health data for these purposes, which are poorly understood, particularly in relation to the new General Data Protection Regulation (GDPR).
This report provides a detailed summary of a panel discussion held at the HTAi 2017 annual meeting in Rome on the current approaches to MIP in Europe, the perceived challenges, and how they could be tackled in the future.
This is OHE’s report to the Charity Commission for England and Wales for the year 2017, OHE’s first since becoming a registered charity in December 2016. It demonstrates some of the ways in which OHE has met its charitable objects: namely, to advance the education of the public in general/health care payers/policy makers on the subject of health economics and health care policy.
A new publication in the European Journal of Health Economics identifies potential challenges of ATMPs in view of current health technology assessment (HTA) methodology and explores potential solutions to these challenges. Three key topics are explored: uncertainty, discounting, and health outcomes and value. A series of recommendations are proposed.
The Center for Global Development and the Office of Health Economics are working on a new approach to drive the next generation of investment for better tuberculosis treatment. Our market-focused approach puts Brazil, Russia, India, China, and South Africa (the BRICS) governments in the driver’s seat—empowering them to send a powerful signal to private-sector pharmaceutical companies about the innovation they value and at the kind of price they are willing to consider.
This OHE Consulting Report reviews “Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS.” The project was funded by the ABPI.
For the year 2015/16, the Treasury reported growth in Government funded healthcare expenditure in the UK of 4.0% whilst NHS Digital reported medicines expenditure growth for the English National Health Service (NHS) for the same period at 8.0%. However, NHS Digital reported much reduced medicines expenditure growth for England of 3.5% for 2016/17, suggesting a complex underlying picture. NHS Digital growth rates are at list price as NHS Digital is not able to take account of rates of discount obtained by the NHS, which our analysis suggests are increasing, or of the rebate payments for branded drugs under the 2014-18 Pharmaceutical Price Regulation Scheme (PPRS).
It is important to stress that we are analysing data to understand trends since 2014. This work does not allow us to make any predictions about future trends.